A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. In June 2021, Novo Nordisk won ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The Food and Drug Administration on Tuesday proposed requiring new nutrition labels on the front of food and beverage products, a long-awaited move aimed at changing eating habits associated with ...

BMI has long been falling out of favor. When the American Medical Association urged downgrading BMI in 2023, it blamed its ...

Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...

The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...

New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...